Mark Harrison

Mark Harrison, AstraZeneca - Qepler Summits And Conferences

Mark Harrison

Principal Analyst
AstraZeneca
Sheffield, United Kingdom
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

I have worked for AstraZeneca for 18 years within Operations, Global Medicines Development.

In my role as a Mass Spectrometry specialist leading pmi analysis and with a focus on extractable and leachable analysis.

My first degree is in Chemistry from Queen Mary University of London, and my I achieved my PhD in Pharmaceutical Chemistry from the The School of Pharmacy and Medicine, University of Bradford.

I have a wide range of international publications covering the areas of trace analysis, separation science, extractables and leachables, genotoxins analysis and mass spectrometry.

Related Sessions:

Qepler - Genotoxic Impurities in Pharmaceuticals Summit thumbnail Details

Genotoxic Impurities in
Pharmaceuticals Summit 2019

GTI strategies & new methodologies: analysis, in silico & regulations. Challenges & opportunities.
  • 11 Apr 2019
  • Berlin, DE
  • Pharma
Day 1: Thursday, 11 April 2019
CASE STUDY: ICH M7 and potential mutagenic impurities; control strategy, analysis and regulatory response.
  • Considerations in a risk assessment and technical position statement.
  • Desired qualities for PMI analytical methodology.
  • When is it applicable to use ICH M7 option 4?
  • Current regulatory challenges
  • Examples of regulatory communications/discussions
View Details
Qepler - 2nd Genotoxic Impurities in Pharmaceuticals Virtual Summit thumbnail Details

2nd Annual Genotoxic Impurities in
Pharmaceuticals Summit 2021

Genotoxic Impurities in Pharmaceuticals strategies & new methodologies: analysis, in silico & regulations.
  • 15 Jul 2021
  • Virtual,
  • Pharma
Day 1: Thursday, 15 July 2021
CASE STUDY: Meeting the challenge of trace analysis of N-nitrosamines -The impact for the pharmaceutical industry.
  • The history of the N-nitrosamine challenge.
  • How has Industry met this challenge?
  • What are the practical measures needed to provide ultra-trace N-nitrosamine data?
View Details
Qepler - 3rd Annual Genotoxic Impurities in Pharmaceuticals Virtual Summit thumbnail Details

3rd Annual Genotoxic Impurities
in Pharmaceuticals Summit 2023

Genotoxic Impurities in Pharmaceuticals strategies & new methodologies: analysis, in silico & regulations.
  • 09 Mar 2023
  • Virtual,
  • Pharma
Day 1: Thursday, 09 March 2023
CASE STUDY: Nitrosamines 2.0: The challenge and impact of nitrosamine trace analysis across the pharmaceutical industry
View Details
This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Cookies Policy.